Post-Menarcheal Height Gain After Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Central Precocious Puberty

INTRODUCTION: Post-menarcheal growth varies by genetic height potential and menarcheal age, but data on residual growth after discontinuing gonadotropin-releasing hormone agonist (GnRHa) treatment in girls with central precocious puberty (CPP) are limited. This study aimed to evaluate menarcheal timing and post-menarcheal height gain after GnRHa treatment discontinuation. METHODS: We retrospectively reviewed 66 girls with CPP treated with GnRHa who had documented menarcheal timing and final adult height (FAH). Auxological and treatment data were collected at treatment initiation, discontinuation, menarche, and FAH. RESULTS: Mean age at treatment initiation, discontinuation, and treatment duration were 7.91±1.22, 10.91±0.34, and 3.02±1.25 years, respectively. Mean bone age (BA) and BA/chronological age (CA) ratio were 9.62 ± 1.62 years and 1.23 ± 0.17 at treatment initiation, and 12.13 ± 0.74 years and 1.08 ± 0.07 at treatment discontinuation, respectively. Menarche occurred at 12.33±0.71 years, 16.36±7.74 months after treatment discontinuation. Mean height at menarche and FAH were 156.92±6.50 cm and 162.52±6.25 cm, respectively. Mean post-menarcheal height gain was 5.55±3.32 cm. Post-menarcheal height gain correlated negatively with the interval from treatment discontinuation to menarche (r= -0.54, p< 0.001), age at menarche (r= -0.34, p= 0.006), and height at menarche (r= -0.33, p= 0.007). Girls with a BA >11 years at GnRHa treatment initiation had a higher first-year growth velocity SDS but a shorter treatment duration, less height gain after treatment discontinuation, lower final adult height and final adult height SDS, and lower final adult height SDS relative to target height (p<0.05 for all). In contrast, none of these parameters differed significantly between the CA groups (<8 vs. ≥8 years), except for treatment duration. CONCLUSION: A longer interval from treatment discontinuation to menarche and greater skeletal maturation at treatment initiation were associated with lower post-menarcheal height gain. These findings may help clinicians counsel families regarding expected menarcheal timing and residual growth after cessation of GnRHa treatment.

Authors

Publication Details

Journal
Hormone Research in Paediatrics
Published
2026-11-20
DOI
https://doi.org/10.1159/hrp/adaag068
Primary Topic
Hypothalamic control of reproductive hormones
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Post-Menarcheal Height Gain After Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Central Precocious Puberty

Büşra Gürpınar Tosun, Tülay Güran, Belma Haliloğlu, Elif Keleştemur et al.
1 links
Hormone Research in Paediatrics
Hypothalamic control of reproductive hormones
article

Post-Menarcheal Height Gain After Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Central Precocious Puberty

Büşra Gürpınar Tosun, Tülay Güran, Belma Haliloğlu, Elif Keleştemur, Abdullah Bereket, Didem Helvacıoğlu, Zehra Yavaş Abalı, Aylin Tugba Canbaz, Sefa Öğe, Serap Turan
article en

Abstract

INTRODUCTION: Post-menarcheal growth varies by genetic height potential and menarcheal age, but data on residual growth after discontinuing gonadotropin-releasing hormone agonist (GnRHa) treatment in girls with central precocious puberty (CPP) are limited. This study aimed to evaluate menarcheal timing and post-menarcheal height gain after GnRHa treatment discontinuation. METHODS: We retrospectively reviewed 66 girls with CPP treated with GnRHa who had documented menarcheal timing and final adult height (FAH). Auxological and treatment data were collected at treatment initiation, discontinuation, menarche, and FAH. RESULTS: Mean age at treatment initiation, discontinuation, and treatment duration were 7.91±1.22, 10.91±0.34, and 3.02±1.25 years, respectively. Mean bone age (BA) and BA/chronological age (CA) ratio were 9.62 ± 1.62 years and 1.23 ± 0.17 at treatment initiation, and 12.13 ± 0.74 years and 1.08 ± 0.07 at treatment discontinuation, respectively. Menarche occurred at 12.33±0.71 years, 16.36±7.74 months after treatment discontinuation. Mean height at menarche and FAH were 156.92±6.50 cm and 162.52±6.25 cm, respectively. Mean post-menarcheal height gain was 5.55±3.32 cm. Post-menarcheal height gain correlated negatively with the interval from treatment discontinuation to menarche (r= -0.54, p< 0.001), age at menarche (r= -0.34, p= 0.006), and height at menarche (r= -0.33, p= 0.007). Girls with a BA >11 years at GnRHa treatment initiation had a higher first-year growth velocity SDS but a shorter treatment duration, less height gain after treatment discontinuation, lower final adult height and final adult height SDS, and lower final adult height SDS relative to target height (p<0.05 for all). In contrast, none of these parameters differed significantly between the CA groups (<8 vs. ≥8 years), except for treatment duration. CONCLUSION: A longer interval from treatment discontinuation to menarche and greater skeletal maturation at treatment initiation were associated with lower post-menarcheal height gain. These findings may help clinicians counsel families regarding expected menarcheal timing and residual growth after cessation of GnRHa treatment.

Hormone Research in Paediatrics
Good health and well-being
Hypothalamic control of reproductive hormones
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon